Back to WXIView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Advanced Solid Tumors With MAPK Pathway Mutations
View Full LandscapeDrug Information
Target Indication
Advanced Solid Tumors With MAPK Pathway Mutations
Clinical Trial
NCT05886920Last updated: 12/16/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Guideline-directed medical therapy (GDMT) for heart failurePhase 3
Pulmonary Hypertension
Mesenchymal Stem CellsPhase 3
Knee Osteoarthritis
CU-20101 treatment for Moderate to Severe Glabellar StriaePhase 3
Glabellar Frown Lines
CU-40102 SprayPhase 3
AGA
5 mg BGM0504 injectionPhase 3
Overweight or Obesity
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts